← NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
Pharmaceutical Preparations · market cap $85M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
NeOnc Technologies Holdings (NTHI) is a small-cap oncology biotech focused on CNS malignancies, with a $117M market cap and three Phase 2 assets targeting diffuse astrocytoma (NEO212), glioblastoma multiforme (perillyl alcohol), and meningioma (NEO100). The company is in a critical financial position with approximately $0.1M cash and less than one month of runway, making near-term financing an existential necessity rather than a discretionary event.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
- 2026-12-30 (est.)Phase 2 · NEO100imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| NEO212 Oral Capsule | Phase 2 | Diffuse Astrocytoma, IDH-Mutant |
| Perillyl alcohol | Phase 2 | Glioblastoma Multiforme |
| NEO100 | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma |
Price & technical context
3-month
-30.8%
6-month
-49.8%
12-month
-66.3%
52-wk range
$2.99–$12.09
vs 50-day MA
-21.1%
vs 200-day MA
-49.7%
Realized vol
110.7%
Max drawdown
-81.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NTHI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.